Ferroptosis in common liver diseases: development of research

doi:10.3877/cma.j.issn.1674-0793.2022.03.016

Abstract

Abstract:

Ferroptosis is an iron-dependent form of cell death characterized by intracellular lipid peroxide accumulation and redox imbalance. Ferroptosis shows specific biological and morphological features when compared to other cell death patterns. The loss of lipid peroxide repair activity by glutathione peroxidase 4 (GPX4), the presence of redox-active iron and the oxidation of polyunsaturated fatty acid (PUFA)-containing phospholipids are considered as distinct fingerprints of ferroptosis. In this review, we report the contribution of ferroptisis to the spectrum of acute or chronic liver diseases. Finally, we discuss the use of ferroptosis as a therapeutic approach against hepatocellular carcinoma, the most common pathological type of primary liver cancer.

Key words: Ferroptosis, Cell death, Liver, Iron metabolism

Sijia Liu, Xiling Zhang, Cuijun Huang, Yunjian Liu. Ferroptosis in common liver diseases: development of research[J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(03): 231-235.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2022.03.016

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2022/V16/I03/231

References 33

[1]	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
[2]	Tang D, Kang R, Berghe TV, et al. The molecular machinery of regulated cell death[J]. Cell Res, 2019, 29(5): 347-364.
[3]	Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future[J]. Cell Death Dis, 2020, 11(2): 88.
[4]	Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J]. Cancer Cell, 2003, 3(3): 285-296.
[5]	Xie Y, Hou W, Song X, et al. Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3): 369-379.
[6]	Shojaie L, Iorga A, Dara L. Cell death in liver diseases: A review[J]. Int J Mol Sci, 2020, 21(24): 9682.
[7]	Pan Y, Tang P, Cao J, et al. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: evidence of ferroptosis induction[J]. Biochem Biophys Res Commun, 2020, 533(4): 1512-1518.
[8]	Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury[J]. Liver Int, 2017, 37(11): 1582-1590.
[9]	Galmiche A. Ferroptosis in Liver Disease//Tang D. Ferroptosis in health and disease[M]. Springer: Cham, 2019: 239-248.
[10]	Yamada N, Karasawa T, Kimura H, et al. Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetaminophen-induced acute liver failure[J]. Cell Death Dis, 2020, 11(2): 144.
[11]	Yan B, Ai Y, Sun Q, et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1[J]. Mol Cell, 2021, 81(2): 355-369. e10.
[12]	Yang W, Wang Y, Zhang C, et al. Maresin1 protect against ferroptosis-induced liver injury through ROS inhibition and Nrf2/HO-1/GPX4 activation[J]. Front Pharmacol, 2022, 13: 865689.
[13]	Gracia-Sancho J, Casillas-Ramírez A, Peralta C. Molecular pathways in protecting the liver from ischaemia/reperfusion injury: A 2015 update[J]. Clin Sci (Lond), 2015, 129(4): 345-362.
[14]	Angeli JPF, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice [J]. Nat Cell Biol, 2014, 16(12): 1180-1191.
[15]	Jiang M, Wu N, Chen X, et al. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease[J]. J Int Med Res, 2019, 47(4): 1453-1466.
[16]	Afonso MB, Castro RE, Rodrigues C. Processes exacerbating apoptosis in non-alcoholic steatohepatitis[J]. Clin Sci (Lond), 2019, 133(22): 2245-2264.
[17]	Loguercio C, De Girolamo V, Sio I, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects[J]. J Hepatol, 2001, 35(5): 568-574.
[18]	Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362(18): 1675-1685.
[19]	Maliken BD, Nelson JE, Klintworth HM, et al. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57(5): 1806-1813.
[20]	Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity[J]. Hepatology, 2002, 36(1): 142-149.
[21]	Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J]. Cell Death Dis, 2019, 10(6): 449.
[22]	You M, Jogasuria A, Lee K, et al. Signal transduction mechanisms of alcoholic fatty liver disease: emer ging role of lipin-1[J]. Curr Mol Pharmacol, 2017, 10(3): 226-236.
[23]	Li LX, Guo FF, Liu H, et al. Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets[J]. Cell Mol Life Sci, 2022 , 79(4): 201.
[24]	Yang L, Wang H, Yang X, et al. Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms[J]. Signal Transduct Target Ther, 2020, 5(1): 138.
[25]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, PMID: 30207593.
[26]	Louandre C, Marcq I, Bouhlal H, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells[J]. Cancer Lett, 2015, 356(2 Pt B): 971-977.
[27]	Li Y, Xia J, Shao F, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis[J]. Biochem Biophys Res Commun, 2021, 534: 877-884.
[28]	Liang C, Zhang X, Yang M, et al. Recent progress in ferroptosis inducers for cancer therapy[J]. Adv Mater, 2019, 31(51): e1904197.
[29]	You A, Cao M, Guo Z, et al. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models[J]. J Hematol Oncol, 2016, 9: 20.
[30]	Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(1): 173-184.
[31]	Nie J, Lin B, Zhou M, et al. Role of ferroptosis in hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2018, 144(12): 2329-2337.
[32]	Yang J, Gong Y, Sontag DP, et al. Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines[J]. Mol Biol Rep, 2018, 45(5): 1023-1036.
[33]	Bai T, Wang S, Zhao Y, et al. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun, 2017, 491(4): 919-925.

Please choose a citation manager

Content to export